


CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (previously presented): A compound represented by formula 1:



wherein

R¹ is selected from the group consisting of H, halogen, (C₁₋₄)alkyl, O(C₁₋₄)alkyl, and haloalkyl;


R² is H or Me;

R³ is H or (C₁₋₄)alkyl;

R⁴ is H or (C₁₋₄)alkyl;

R⁵ is (C₁₋₄)alkyl, (C₁₋₄)alkyl(C₃₋₇)cycloalkyl, or (C₃₋₇)cycloalkyl; and

W is selected from:




wherein,

a) one of **Y** is SO₂ and the other **Y** is NR⁶, provided that both are not the same, wherein **R⁶** is selected from the group consisting of: H, C(O)O(C₁₋₄)alkyl, (C₁₋₄) alkyl or (C₁₋₄) alkyl substituted with either a pyridinyl-N-oxide or C(O)OR⁸ wherein **R⁸** is H or (C₁₋₄) alkyl; and each **R⁹** is independently H or (C₁₋₄) alkyl; and

b) **E** is $\text{CR}^{10}\text{R}^{10}$ wherein each R^{10} is independently H or (C_{1-4}) alkyl, **J** is CH_2 and the dotted line represents a single bond; or

c) **E** and **J** are both CR^{11} wherein R^{11} is H or (C_{1-4}) alkyl and the dotted line represents a double bond; or

W is selected from:



wherein,


m is 1 or 2,

R^{12} is H or (C_{1-4}) alkyl,

R^{13} is H or (C_{1-4}) alkyl, and

Z is O or Z is NR^{14} wherein R^{14} is H or (C_{1-4}) alkyl; or

W is selected from a group of aromatic radicals consisting of:




wherein R^{15} is (C_{1-4}) alkyl or CF_3 , and n is the integer 0, 1 or 2, or a pharmaceutically acceptable salt or ester thereof.


Claim 2 (original): The compound according to claim 1, wherein R^1 is selected from

the group consisting of: H, Cl, F, (C₁₋₄) alkyl and CF₃; R², R³ and R⁴ is each independently H or Me; R⁵ is ethyl or cyclopropyl;




W is:




wherein Y is SO₂ and the other Y is NR⁶, provided that both are not the same, R⁶ is H, C(O)OMe, C(O)OEt, (4-pyridinyl-N-oxide)methyl, CH₂C(O)OH, CH₂C(O)OMe, CH₂C(O)OEt or CH₂C(O)OCMe₃, and each R⁹ is independently H or Me; or



wherein E is CR¹⁰R¹⁰ wherein each of R¹⁰ is independently H or Me, J is CH₂ and the dotted line represents a single bond; or both E and J are CR¹¹ wherein R¹¹ is H or Me and the dotted line represents a double bond; one of Y is SO₂ and the other Y is NR⁶ wherein R⁶ is hydrogen or methyl; or



or




wherein R¹⁵ is Me or Et, and n is 0 or 1.


Claim 3 (original): The compound according to claim 2, wherein \mathbf{R}^{15} is Me.

Claim 4 (original): The compound according to claim 3, wherein \mathbf{R}^1 is H, Cl, F and Me; \mathbf{R}^2 is H or Me;


\mathbf{W} is:



Claim 5 (original): The compound according to claim 4, wherein \mathbf{R}^3 is Me, \mathbf{R}^6 is H, C(O)OEt or (4-pyridinyl-N-oxide)methyl, and \mathbf{W} is:



Claim 6 (currently amended): The compound according to ~~claim 4~~ claim 3, wherein \mathbf{W} is:



wherein one **Y** is SO_2 and the other **Y** is NR^6 , provided that both are not the same, R^6 is H, $\text{C}(\text{O})\text{OEt}$, $\text{CH}_2\text{C}(\text{O})\text{OH}$, $\text{CH}_2\text{C}(\text{O})\text{OCMe}_3$, (4-pyridinyl-N-oxide)methyl; and each R^9 is independently H or Me.

Claim 7 (original): The compound according to claim 6, wherein R^6 is H and each R^9 is Me.

Claim 8 (cancelled)

Claim 9 (cancelled)

Claim 10 (cancelled)


Claim 11 (previously presented): A pharmaceutical composition for the treatment of HIV infection, comprising a compound of formula 1 according to claim 1, or a pharmaceutically acceptable salt or ester thereof, in combination with a pharmaceutically acceptable carrier.

Claim 12 (previously presented): A method for the treatment of HIV infection, comprising administering to a patient an HIV inhibiting amount of a compound of formula 1 according to claim 1, or a pharmaceutically acceptable salt or ester thereof.





Claim 13 (previously presented): A method for the treatment of HIV infection, comprising administering to a patient an HIV inhibiting amount of a pharmaceutical composition according to claim 11.


Claim 14 (previously presented): A process for producing a compound of formula 1 according to claim 1, comprising the step:

- coupling a compound of formula 2:



wherein **R¹, R², R³, R⁴, and R⁵** are as defined in claim 1, with a phenolic derivative selected from:






wherein PG¹ is a nitrogen protecting group and PG² is a carboxy protecting group, said protecting groups being removable under mildly acidic, mildly alkaline or reductive conditions, and R⁶, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, m, n, and Z are as defined in claim 1.

Claim 15 (currently amended): The process according to claim 14, wherein said ~~nitrogen protecting group~~ carboxy protecting group is selected from: alkyl esters; aralkyl esters; and esters that can be cleaved by mild base treatment or mild reductive means.

Claim 16 (currently amended): The process according to claim 14, wherein said ~~carboxy protecting group~~ nitrogen protecting group is selected from: Boc (*tert*-butyloxycarbonyl) and alkyl carbamates.

Claim 17 (original): An intermediate compound of formula 2:



wherein **R**¹, **R**², **R**³, **R**⁴, and **R**⁵ are as defined in claim 1.